Research & Development Investments Do Not Explain Drug Price Variation
MONDAY, Oct. 3, 2022 (HealthDay News) -- For a sample of 60 drugs, research and development investments do not explain the variation in list prices, according to a study published online Sept. 26 in JAMA Network Open.
Olivier J. Wouters, Ph.D., from the London School of Economics and Political Science, and colleagues conducted a cross-sectional study analyzing 60 drugs approved by the U.S. Food and Drug Administration between Jan. 1, 2009, and Dec. 31, 2018, to examine the association between treatment costs and research and development investments.
The researchers observed no association between estimated research and development investments and log-adjusted treatment costs based on list prices at launch or net prices one year after launch. When 2021 prices were used to estimate treatment costs, this result held. No association was seen between estimated research and development investments and log-adjusted treatment at launch in the fully adjusted model or from 2021 in linear regression models.
"Drug companies should supply further data to support claims that high drug prices are needed to recover research and development investments, if this argument will continue to be used to justify high prices," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Related Posts
Millones de toneladas de máscaras y guantes para la COVID acabarán en los océanos
MARTES, 9 de noviembre de 2021 (HealthDay News) -- Aunque los cierres de la...
U.S. to Tighten Control of PFAS Chemicals in Drinking Water
TUESDAY, March 14, 2023 (HealthDay News) -- U.S. water utilities will be...
AHA News: Statistics Report Offers Snapshot of the Nation’s Brain Health – And a Guide to Protecting It
WEDNESDAY, Jan. 26, 2022 (American Heart Association News) -- Brain diseases,...
Asesinos silenciosos: los calefactores y los generadores conllevan un peligro de monóxido de carbono
https://consumer.healthday.com/b-12-19-silent-kill... Credit: HealthDay